• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过脒基苯并噻吩衍生物的三维定量构效关系设计和预测新型抗凝剂作为选择性凝血因子IXa抑制剂。

Design and prediction of new anticoagulants as a selective Factor IXa inhibitor via three-dimensional quantitative structure-property relationships of amidinobenzothiophene derivatives.

作者信息

Gao Jia-Suo, Tong Xu-Peng, Chang Yi-Qun, He Yu-Xuan, Mei Yu-Dan, Tan Pei-Hong, Guo Jia-Liang, Liao Guo-Chao, Xiao Gao-Keng, Chen Wei-Min, Zhou Shu-Feng, Sun Ping-Hua

机构信息

Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, People's Republic of China.

College of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.

出版信息

Drug Des Devel Ther. 2015 Mar 23;9:1743-59. doi: 10.2147/DDDT.S75282. eCollection 2015.

DOI:10.2147/DDDT.S75282
PMID:25848211
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4376188/
Abstract

Factor IXa (FIXa), a blood coagulation factor, is specifically inhibited at the initiation stage of the coagulation cascade, promising an excellent approach for developing selective and safe anticoagulants. Eighty-four amidinobenzothiophene antithrombotic derivatives targeting FIXa were selected to establish three-dimensional quantitative structure-activity relationship (3D-QSAR) and three-dimensional quantitative structure-selectivity relationship (3D-QSSR) models using comparative molecular field analysis and comparative similarity indices analysis methods. Internal and external cross-validation techniques were investigated as well as region focusing and bootstrapping. The satisfactory q (2) values of 0.753 and 0.770, and r (2) values of 0.940 and 0.965 for 3D-QSAR and 3D-QSSR, respectively, indicated that the models are available to predict both the inhibitory activity and selectivity on FIXa against Factor Xa, the activated status of Factor X. This work revealed that the steric, hydrophobic, and H-bond factors should appropriately be taken into account in future rational design, especially the modifications at the 2'-position of the benzene and the 6-position of the benzothiophene in the R group, providing helpful clues to design more active and selective FIXa inhibitors for the treatment of thrombosis. On the basis of the three-dimensional quantitative structure-property relationships, 16 new potent molecules have been designed and are predicted to be more active and selective than Compound 33, which has the best activity as reported in the literature.

摘要

凝血因子IXa(FIXa)在凝血级联反应的起始阶段受到特异性抑制,这为开发选择性和安全性良好的抗凝剂提供了一种极佳的方法。选择了84种靶向FIXa的脒基苯并噻吩抗血栓衍生物,采用比较分子场分析和比较相似性指数分析方法建立三维定量构效关系(3D-QSAR)和三维定量构-选择性关系(3D-QSSR)模型。研究了内部和外部交叉验证技术以及区域聚焦和自举法。3D-QSAR和3D-QSSR的q(2)值分别为0.753和0.770,r(2)值分别为0.940和0.965,表明这些模型可用于预测对FIXa相对于Xa因子(X因子的活化状态)的抑制活性和选择性。这项工作表明,在未来的合理设计中应适当考虑空间、疏水和氢键因素,特别是R基团中苯的2'-位和苯并噻吩的6-位的修饰,为设计更具活性和选择性的用于治疗血栓形成的FIXa抑制剂提供了有用的线索。基于三维定量结构-性质关系,设计了16种新的强效分子,预计它们比文献报道中活性最佳的化合物33更具活性和选择性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a31f/4376188/8c0cb82147cb/dddt-9-1743Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a31f/4376188/01e3bc451037/dddt-9-1743Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a31f/4376188/778f7bb3824f/dddt-9-1743Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a31f/4376188/50ad80b9afd3/dddt-9-1743Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a31f/4376188/17fe114a35e6/dddt-9-1743Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a31f/4376188/8c0cb82147cb/dddt-9-1743Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a31f/4376188/01e3bc451037/dddt-9-1743Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a31f/4376188/778f7bb3824f/dddt-9-1743Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a31f/4376188/50ad80b9afd3/dddt-9-1743Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a31f/4376188/17fe114a35e6/dddt-9-1743Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a31f/4376188/8c0cb82147cb/dddt-9-1743Fig5.jpg

相似文献

1
Design and prediction of new anticoagulants as a selective Factor IXa inhibitor via three-dimensional quantitative structure-property relationships of amidinobenzothiophene derivatives.通过脒基苯并噻吩衍生物的三维定量构效关系设计和预测新型抗凝剂作为选择性凝血因子IXa抑制剂。
Drug Des Devel Ther. 2015 Mar 23;9:1743-59. doi: 10.2147/DDDT.S75282. eCollection 2015.
2
Molecular modeling studies of [6,6,5] Tricyclic Fused Oxazolidinones as FXa inhibitors using 3D-QSAR, Topomer CoMFA, molecular docking and molecular dynamics simulations.使用3D-QSAR、拓扑异构体CoMFA、分子对接和分子动力学模拟对[6,6,5]三环稠合恶唑烷酮作为凝血因子Xa抑制剂进行分子建模研究。
Bioorg Med Chem Lett. 2015 Oct 15;25(20):4522-8. doi: 10.1016/j.bmcl.2015.08.070. Epub 2015 Aug 28.
3
Discovery of FIXa inhibitors by combination of pharmacophore modeling, molecular docking, and 3D-QSAR modeling.通过药效团建模、分子对接和三维定量构效关系建模相结合的方法发现FIXa抑制剂。
J Recept Signal Transduct Res. 2018 Jun;38(3):213-224. doi: 10.1080/10799893.2018.1468784. Epub 2018 May 4.
4
A Structure Based Study of Selective Inhibition of Factor IXa over Factor Xa.基于结构的因子 IXa 选择性抑制因子 Xa 的研究。
Molecules. 2021 Sep 3;26(17):5372. doi: 10.3390/molecules26175372.
5
Investigation on the binding mode of benzothiophene analogues as potent factor IXa (FIXa) inhibitors in thrombosis by CoMFA, docking and molecular dynamic studies.通过 CoMFA、对接和分子动力学研究,探讨苯并噻吩类似物作为强效凝血因子 IXa (FIXa)抑制剂在血栓形成中的结合模式。
J Enzyme Inhib Med Chem. 2011 Dec;26(6):792-804. doi: 10.3109/14756366.2011.554414. Epub 2011 Mar 7.
6
Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa.3-脒基苄基-1H-吲哚-2-甲酰胺作为凝血因子Xa的强效、非手性和选择性抑制剂的设计及定量构效关系
J Med Chem. 2002 Jun 20;45(13):2749-69. doi: 10.1021/jm0111346.
7
Design, synthesis and structure-activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors.含新型S4配体的恶唑烷酮衍生物作为凝血因子Xa抑制剂的设计、合成及构效关系
Eur J Med Chem. 2015;96:369-80. doi: 10.1016/j.ejmech.2015.04.025. Epub 2015 Apr 16.
8
Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.基于三维定量构效关系比较分子场分析/比较分子相似性指数分析模型对尿激酶型纤溶酶原激活剂抑制剂结构要求的洞察。
J Med Chem. 2006 Jan 26;49(2):475-89. doi: 10.1021/jm050149r.
9
Synthesis of 3,4-diaminobenzoyl derivatives as factor Xa inhibitors.作为凝血因子Xa抑制剂的3,4-二氨基苯甲酰衍生物的合成。
Eur J Med Chem. 2015 Aug 28;101:41-51. doi: 10.1016/j.ejmech.2015.06.012. Epub 2015 Jun 17.
10
Understanding the structure-activity and structure-selectivity correlation of cyclic guanine derivatives as phosphodiesterase-5 inhibitors by molecular docking, CoMFA and CoMSIA analyses.通过分子对接、比较分子场分析(CoMFA)和比较分子相似性指数分析(CoMSIA)来理解环状鸟嘌呤衍生物作为磷酸二酯酶-5抑制剂的构效关系和结构选择性关系。
Bioorg Med Chem. 2006 Mar 1;14(5):1462-73. doi: 10.1016/j.bmc.2005.09.073. Epub 2005 Nov 2.

本文引用的文献

1
Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.比较分子场分析(CoMFA)。1. 形状对类固醇与载体蛋白结合的影响。
J Am Chem Soc. 1988 Aug 1;110(18):5959-67. doi: 10.1021/ja00226a005.
2
Exploring QSARs for 5-lipoxygenase (5-LO) inhibitory activity of 2-substituted 5-hydroxyindole-3-carboxylates by CoMFA and CoMSIA.用 CoMFA 和 CoMSIA 探索 2-取代 5-羟基吲哚-3-羧酸酯对 5-脂氧合酶(5-LO)抑制活性的定量构效关系(QSARs)。
Chem Biol Drug Des. 2011 Aug;78(2):314-21. doi: 10.1111/j.1747-0285.2011.01146.x. Epub 2011 Jun 13.
3
Investigation on the binding mode of benzothiophene analogues as potent factor IXa (FIXa) inhibitors in thrombosis by CoMFA, docking and molecular dynamic studies.
通过 CoMFA、对接和分子动力学研究,探讨苯并噻吩类似物作为强效凝血因子 IXa (FIXa)抑制剂在血栓形成中的结合模式。
J Enzyme Inhib Med Chem. 2011 Dec;26(6):792-804. doi: 10.3109/14756366.2011.554414. Epub 2011 Mar 7.
4
New parenteral anticoagulants in development.正在研发的新型胃肠外抗凝剂。
Ther Adv Cardiovasc Dis. 2011 Feb;5(1):33-59. doi: 10.1177/1753944710387808. Epub 2010 Nov 2.
5
Nitrophorin 2, a factor IX(a)-directed anticoagulant, inhibits arterial thrombosis without impairing haemostasis.硝呋啉 2 是一种因子 IX(a)导向的抗凝剂,可抑制动脉血栓形成而不损害止血功能。
Thromb Haemost. 2010 Dec;104(6):1116-23. doi: 10.1160/th10.1160/th10-03-0186. Epub 2010 Sep 13.
6
Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis.苯并噻吩模板作为血栓形成中强效因子 IXa(FIXa)抑制剂的研究。
J Med Chem. 2010 Feb 25;53(4):1465-72. doi: 10.1021/jm901475e.
7
Structure based drug design: development of potent and selective factor IXa (FIXa) inhibitors.基于结构的药物设计:强效和选择性因子 IXa(FIXa)抑制剂的开发。
J Med Chem. 2010 Feb 25;53(4):1473-82. doi: 10.1021/jm901476x.
8
Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex.肝素激活的抗凝血酶识别因子 IXa 的分子基础通过三元复合物的 1.7A 结构揭示。
Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):645-50. doi: 10.1073/pnas.0910144107. Epub 2009 Dec 22.
9
CoMFA and CoMSIA 3D-QSAR analysis of DMDP derivatives as anti-cancer agents.作为抗癌剂的DMDP衍生物的比较分子场分析(CoMFA)和比较分子相似性指数分析(CoMSIA)三维定量构效关系分析
Bioinformation. 2008 Jun 27;2(9):384-91. doi: 10.6026/97320630002384.
10
Three-dimensional quantitative structure activity relationships of quorum-sensing and biofilm inhibitors in gram-negative bacteria.
J Environ Sci Health B. 2008 May;43(4):281-7. doi: 10.1080/03601230801941584.